Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -256.99% | -230.31% | -76.82% | -18.21% | 5.62% |
| Total Depreciation and Amortization | 150.35% | 356.36% | 5,574.24% | 5,353.03% | 5,165.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 473.45% | 581.03% | 300.62% | 1,124.53% | 112.49% |
| Change in Net Operating Assets | 86.36% | 39.14% | -390.29% | -444.52% | -1,329.35% |
| Cash from Operations | -187.01% | -172.54% | -91.43% | -52.94% | 4.00% |
| Capital Expenditure | 30.97% | -82.64% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.34% | -723.61% | 144.82% | -- | -476.99% |
| Cash from Investing | -63.70% | -716.36% | 144.35% | -- | -480.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.94% | -89.06% | -81.43% | -81.45% | 1,246,973.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 102.13% | 46.59% | -- | -- | -103.20% |
| Cash from Financing | -86.16% | -89.30% | -82.37% | -82.41% | 406.91% |
| Foreign Exchange rate Adjustments | 77.43% | 269.32% | -56.17% | 225.06% | -298.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -145.77% | -165.77% | -79.24% | -138.87% | 888.77% |